Tirzepatide Monthly Weight Loss Program

$449.99$599.99 or from $404.99$539.99 / month for 3 months

Weekly injection
GIP and GLP-1 receptor agonist
Reduces A1 C
Increases insulin secretion
Suppress appetite
Mimics hunger cue in the brain



***New Patients Need to Start at Step 1

SKU: N/A Category:

Tirzepatide, also known as Mounjaro™, is a GLP-1 drug that is taken once-weekly as an injectable to promote weight loss by regulating blood sugars and reducing hemoglobin A1C levels. Tirzepatide works similarly to the other drugs in the GLP-1 family, but it contains an extra molecule that may give it a slight edge.

The medication has a dual-action design, mimicking the action of two unique incretin hormones involved in blood sugar control: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This unique dual action makes it the first-in-class medication that acts on both of these receptors.

GIP is a hormone that may complement the effects of GLP-1 receptor agonists. In preclinical models, GIP has been shown to decrease food intake and increase energy expenditure, therefore resulting in weight reductions. When combined with the GLP-1 receptor agonist, GIP usage may have a greater impact on markers of metabolic dysregulation, such as body weight, glucose and lipids.

On average, patients lose up to 22.5% of their body weight on this program.